A Study of Durvalumab With or Without Tremelimumab in Endometrial Cancer
Status:
Active, not recruiting
Trial end date:
2022-01-01
Target enrollment:
Participant gender:
Summary
This study will test the safety and efficacy of the experimental drug called durvalumab with
or without another experimental drug called tremelimumab in endometrial cancer.